Skip to main contentAI and Advanced
/
ANUHPHR · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
AN
NSE · Equity shares · Biotechnology & Drugs-1.11 · -1.23%
Anuh Pharma ANUHPHR
NSE:INR 89.22
BSE:INR 88.81
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ANUHPHR
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 90.33
Day rangeINR 87.01 — INR 91.99
52-week rangeINR 66.72 — INR 107.75
Volume1.41 L
Market cap786.26
P/E16.34
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)771.66
Net Income (INR Cr)41.05
Rev Growth (5 Year %)12.3
EPS Growth (5 Year %)7.64
P/E Ratio16.34
Book Value35.09
EPS4.1
Price/BV2.54Computed
Research path: Interpret Anuh Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ANUHPHRAnuh Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 557.37 | 506.63 | 445.68 |
| Cash Equivalents | 0.24 | Not available | Not available |
| Other Liabilities Total | 2.14 | 2.03 | 1.38 |
| Common Stock Total | 50.11 | 25.06 | 25.06 |
| Other Current Assets Total | 10 | 0.18 | 2.47 |
| Total Assets | 557.37 | 506.63 | 445.68 |
| Current Portof LT Debt/Capital Leases | 0.06 | 0.33 | 0.29 |
| Cash | 8.06 | 19.56 | 7.2 |
| Total Equity | 352.22 | 326.02 | 291.22 |
| Long Term Investments | 45.42 | 61.95 | 51.71 |
| Retained Earnings(Accumulated Deficit) | 302.11 | 300.93 | 266.11 |
| Total Common Shares Outstanding | 10.02 | 10.02 | 10.02 |
| Tangible Book Valueper Share Common Eq | 35.09 | 32.52 | 29.04 |
| Total Liabilities | 205.15 | 180.6 | 154.46 |
| Total Debt | 0.06 | 10.89 | 2.69 |
| Short Term Investments | 45.8 | 53.86 | 55.05 |
| Cashand Short Term Investments | 54.1 | 73.41 | 62.26 |
| Total Receivables Net | 239.46 | 226.19 | 193.14 |
| Notes Payable/Short Term Debt | 0 | 10.5 | 2.01 |
| Accounts Receivable-Trade Net | 238.63 | 216.1 | 190.16 |
| Property/Plant/Equipment Total-Net | 56.09 | 58.37 | 49.24 |
| Total Current Liabilities | 203 | 178.51 | 152.69 |
| Total Inventory | 147.76 | 74.61 | 77.74 |
| Accounts Payable | 187.66 | 156.84 | 140.5 |
| Other Currentliabilities Total | 15.29 | 10.3 | 9.41 |
| Total Long Term Debt | 0 | 0.06 | 0.39 |
| Intangibles Net | 0.53 | 0.12 | 0.16 |
| Other Long Term Assets Total | 3.92 | 9.86 | 4.52 |
| Note Receivable-Long Term | 0.09 | 0.16 | 3.85 |
| Total Current Assets | 451.32 | 376.17 | 336.2 |
| Capital Lease Obligations | 0 | 0.06 | 0.39 |
| Accumulated Depreciation Total | Not available | -60.78 | -54.72 |
| Accrued Expenses | Not available | 0.54 | 0.48 |
| Other Equity Total | Not available | 0.04 | 0.06 |
| Prepaid Expenses | Not available | 1.77 | 0.59 |
| Property/Plant/Equipment Total-Gross | Not available | 118.88 | 103.51 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio4.5
Price to Sale Ratio1.02
Growth
Debt 5Yr CAGR %-66.43
Margins
Operating Margin 12m6.52
Operating Margin 5y Avg8.17
Net Profit Margin 12m5.32
Net Profit Margin 5y6.95
Yield
Dividend Yield %1.87
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk35.87
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,937.85 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,385.25 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,994.45 | 1.69 L | 72.73 | — |
| Cipla | INR 1,408.1 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,119.45 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 71.80%
- FII
- 0.01%
- Other
- 28.19%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Anuh Pharma FY26 Revenue Grows 16% to ₹776 Cr, Profit Declines - WhalesbookMarket news · 18 Jul 2026, 4:37 pm
Anuh Pharma FY26 Revenue Grows 16% to ₹776 Cr, Profit Declines Whalesbook
Anuh Pharma declares ₹1.50 dividend, schedules AGM on Aug 12 - scanx.tradeMarket news · 18 Jul 2026, 4:29 pm
Anuh Pharma declares ₹1.50 dividend, schedules AGM on Aug 12 scanx.trade
Wanbury Ltd Spurts 3.27% - Business StandardMarket news · 15 Jul 2026, 10:05 am
Wanbury Ltd Spurts 3.27% Business Standard
Anuh Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals - MarketsMojoMarket news · 14 Jul 2026, 1:52 am
Anuh Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals MarketsMojo
Anuh Pharma Ltd is Rated Sell - MarketsMojoMarket news · 7 Jul 2026, 6:08 am
Anuh Pharma Ltd is Rated Sell MarketsMojo
Anuh Pharma Ltd Technical Analysis: Momentum Shifts Signal Bearish Outlook - MarketsMojoMarket news · 7 Jul 2026, 2:13 am
Anuh Pharma Ltd Technical Analysis: Momentum Shifts Signal Bearish Outlook MarketsMojo
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.1.5000 per share(30%)Final Dividend
- board MeetingsAudited Results, Final Dividend & A.G.M.
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.5000 per share(30%)Final Dividend (RD date revised)
- board MeetingsTo consider other business matters.
Rusaka Markets Community
Discussion and sentiment for Anuh Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Anuh Pharma Limited is engaged in the business of manufacturing and selling bulk drugs and chemicals. The Company's products include active pharmaceutical ingredients and corticosteroids. Its active pharmaceutical ingredients include macrolides, anti-TB, anti-malarial, antibacterial, anti-hypertension, expectorant, quinolones, intermediates and under development. Its macrolides products include erythromycin, erythromycin ethyl succinate, erythromycin stearate, erythromycin estolate, erythromycin propionate, erythromycin phosphate, and others. Its anti-malarial products include sulfadoxine, pyrimethamine, and others. The Company's anti-hypertension products include losartan potassium, telmisartan and atorvastatin calcium. The Company's corticosteroids include anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, antihistamines and under development. Its anti-inflammatory products include dexamethasone Na phosphate, mometasone furoate and clobetasol butyrate.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ANUHPHR
- BSE Code
- 506260
Questions
Stock FAQ
What is the symbol and ISIN of Anuh Pharma?
Anuh Pharma has the symbol ANUHPHR and ISIN - INE489G01022.
What is the current price of Anuh Pharma?
Anuh Pharma is currently trading at INR 89.22.
What are the year high and year low of Anuh Pharma?
Anuh Pharma has a year high of INR 107.75 and a year low of INR 66.72.
What is the market capitalization of Anuh Pharma?
Anuh Pharma has a market capitalization of INR 786.26 crore.
What is the P/E ratio of Anuh Pharma?
Anuh Pharma has a P/E ratio of 16.34.
What is the dividend yield of Anuh Pharma?
Anuh Pharma has a dividend yield of 1.87%.
How is the financial performance of Anuh Pharma based on revenue, net income, and EPS?
Anuh Pharma has revenue of INR 771.66 crore, net income of INR 41.05 crore, and EPS of INR 4.10.
What is the book value of Anuh Pharma?
Anuh Pharma has a book value of INR 35.09.
What is the debt-to-equity ratio of Anuh Pharma?
Anuh Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Anuh Pharma?
Anuh Pharma has a price-to-book ratio of 2.54 and a price-to-sales ratio of 1.02.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.